과소 진행성 비소 세포 폐암, 흑색 종 및 신장 세포 암종 치료를위한 양전자 방출 단층 촬영 (PET) 유도 정위 체부 방사선 요법
과소 진행성 비소 세포 폐암, 흑색 종 및 신장 세포 암종에서 생물학적 유도 정위 체부 방사선 요법의 2 상 무작위 통제 시험
This phase II trial tests the safety of positron emission tomography (PET) guided stereotactic body radiation therapy (SBRT) and how well it works to treat non-small cell lung cancer (NSCLC), melanoma, and renal cell carcinoma (RCC) that has up to 5 sites of progression (oligoprogression) compared to standard SBRT. SBRT uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. A PET scan is an imaging test that looks at your tissues and organs using a small amount of a radioactive substance. It also checks for cancer and may help find cancer remaining in areas already treated. Using a PET scan for SBRT planning may help increase the dose of radiation given to the most resistant part of the cancer in patients with oligoprogressive NSCLC, melanoma, and RCC.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
PRIMARY OBJECTIVE:
I. PET adaptive SBRT is both feasible and safe and allows for a higher total dose of radiation through an inter-fraction simultaneous integrated boost (SIB) based on inter-fraction PET uptake, leading to improved local control outcomes compared to current standard SBRT planning without a SIB.
SECONDARY OBJECTIVES:
I. Determine the duration of local and distant control followed PET adaptive SBRT treatment compared to standard external beam radiation therapy (EBRT).
II. Evaluate the utility of measuring circulating tumor deoxyribonucleic acid (DNA) (ctDNA) before, during and after SBRT in conjuction with biological imaging to assess early disease response.
III. Identify genomic predictors to predict for distant progression. IV. Determine durability of current systemic therapy with SBRT to oligoprogressive sites.
EXPLORATORY OBJECTIVES:
I. Biomarker changes based on ctDNA before, during and after treatment. II. Changes in fludeoxyglucose (FDG) uptake with SBRT and combined checkpoint inhibitor during and after treatment and correlation with local and distant control.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients undergo 5 SBRT treatments every other day on study. Patients also undergo computed tomography (CT) or PET/CT and blood collection throughout study.
ARM II: Patients undergo 3 SBRT treatments every other day week 1, undergo PET/CT and replanning one month post SBRT, then undergo 2 additional treatments with SIB on study. Patients also undergo CT or PET/CT and blood collection throughout study.
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
California
-
Duarte, California, 미국, 91010
- 모병
- City of Hope Medical Center
-
수석 연구원:
- Arya Amini
-
연락하다:
- Arya Amini
- 전화번호: 626-218-4589
- 이메일: aamini@coh.org
-
Irvine, California, 미국, 92618
- 모병
- City of Hope at Irvine Lennar
-
연락하다:
- Arya Amini
-
연락하다:
- Arya Amini, MD
- 전화번호: 626-218-4673
- 이메일: aamini@coh.org
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
Documented informed consent of the participant and/or legally authorized representative
- Assent, when appropriate, will be obtained per institutional guidelines
-
Agreement to allow the use of archival tissue from diagnostic tumor biopsies
- If unavailable, exceptions may be granted with study principal investigator (PI) approval
-
Age: >= 18 years
-
Eastern Cooperative Oncology Group (ECOG) =< 2
-
Histologically or cytologically confirmed NSCLC with 1-5 sites of disease progression while on or following systemic therapy with a checkpoint inhibitor with or without chemotherapy for at least 3 months with radiographic evidence of progression based on Response Evaluation Criteria in Solid Tumors (RECIST) or Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST)
-
Lesion(s) must all be amenable to SBRT which will be determined by the radiation oncologists. Active lesions should be a minimum size of >= 1 cm
-
Primary tumor should be controlled for > 3 months in the metachronous setting; for synchronouos progression of the primary and oligoprogressive site(s), the primary should be treated with curative/local control intent
-
Patients eligible for the study must have at least one lesion for which the planned radiation dose achieves a biologic effective dose (BED) < 100 (alpha/beta = 10) due to organs at risk and dose constraints
-
If the clinical scenario deem that other forms of local therapy may be more suitable for the metastatic disease, such as surgical resection and interventional radiology-guided ablation, patients would be able to undergo other forms of local therapy after discussion with the study PI but at least one lesion must be treated with SBRT in this scenario
-
Patients with brain metastases can be included but brain metastases must be treated prior to enrollment and are not considered as a site of oligoprogression
-
Life expectancy >= 3 months in the opinion of the treating investigators
Exclusion Criteria:
- Judgement by the investigator that the patient is unsuitable to participate in the study and the patient is unlikely to comply with study procedures, restrictions, and requirements
- Those not eligible for SBRT after review by a radiation oncologist
- Unable to undergo a Pet/CT or do not have Pet active disease
- Pregnant and/or breastfeeding women are excluded from this study as these agents may have the potential for teratogenic or abortifacient effects. Female patients of childbearing potentially must have a negative urine or serum pregnancy test within 72 hours prior to receiving therapy
- Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: ARM I: (standard care SBRT)
Patients undergo 5 SBRT treatments every other day on study. Patients also undergo CT or PET/CT and blood collection throughout study. |
Ancillary studies Undergo PET
다른 이름들:
Undergo CT or PET/CT
다른 이름들:
Undergo blood collection
다른 이름들:
Undergo SBRT
다른 이름들:
|
|
실험적: ARM II: (PET guided SBRT)
ARM II: Patients undergo 3 SBRT treatments every other day week 1, undergo PET/CT and replanning one month post SBRT, then undergo 2 additional treatments with SIB on study. Patients also undergo CT or PET/CT and blood collection throughout study. |
Ancillary studies Undergo PET
다른 이름들:
Undergo CT or PET/CT
다른 이름들:
Undergo blood collection
다른 이름들:
Undergo SBRT
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Feasibility and safety of positron emission tomography (PET) adaptive stereotactic body radiation therapy (SBRT)
기간: At completion of SBRT up to 5 weeks
|
Feasibility and safety of biologically-guided adaptive planning based on the standardized uptake value (SUV) on pre-treatment and inter-fraction FDG-PET/CT to guide SBRT dose-escalation with a simultaneous integrated boost (SIB) delivered to areas of higher activity in patients with oligoprogressive (1-5 sites) disease when compared to the current standard SBRT planning without inter-fraction adaptive planning, with the goal of demonstrating that PET-adaptive inter-fraction planning can improve total dose delivered over the course of treatment. We will be measuring the difference in total radiation dose in Gy between the two arms with the goal of achieving an absolute dose of 10 Gy or higher. |
At completion of SBRT up to 5 weeks
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
전반적인 생존
기간: 최대 12개월
|
최대 12개월
|
|
|
다음 전신 요법까지의 시간
기간: 최대 12개월
|
최대 12개월
|
|
|
Time to progression
기간: Up to 12 months
|
Defined as time of randomization to disease progression at any site or death. Assessed using the modified Response Evaluation Criteria in Solid Tumors (mRECIST). |
Up to 12 months
|
|
Quality of life (QOL)
기간: Up to 12 months
|
Patient reported outcomes using the Functional Assessment of Cancer Therapy - G. Baseline changes in reported QOL will be summarized. Repeated QOL assessments will be tabulated and graphically displayed to describe the changes of QOL outcomes over time, no formal hypothesis testing is planned. An evaluation by dose, response and other characteristics may also be considered. For quantitative QOL scales, data will be represented using means/ medians, histogram/ boxplots. The area under curve will be used as a summary score for each patient. These can then be averaged across groups for informal assessment. Standard imputation methods will be used to deal with a large proportion of missing data. |
Up to 12 months
|
|
Incidence of adverse events
기간: At 3, 6, and 12 months following radiation therapy
|
Clinician documented toxicity using common terminology for adverse events version 5. |
At 3, 6, and 12 months following radiation therapy
|
|
Local control rates
기간: Up to 12 months
|
Assessed using the mRECIST. |
Up to 12 months
|
|
Dose delivered
기간: Up to 12 months
|
Defined as the dose delivered in the experimental group for the first 3 fractions versus the dose given for the last 2 fractions. |
Up to 12 months
|
공동 작업자 및 조사자
협력자
협력자
수사관
수사관
- 수석 연구원: Arya Amini, City of Hope Medical Center
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
- 비뇨생식기 질환
- 비뇨생식기 신생물
- 부위별 신생물
- 신생물
- 남성 비뇨 생식기 질환
- 신장 질환
- 비뇨기과 질환
- 여성 비뇨 생식기 질환
- 여성 비뇨 생식기 질환 및 임신 합병증
- 호흡기 질환
- 조직학적 유형에 따른 신생물
- 폐 질환
- 신생물, 선상 및 상피
- 선암종
- 호흡기 신생물
- 흉부 신생물
- 폐 신생물
- 피부병
- 비뇨기과 신생물
- 암종
- 신경외배엽 종양
- 신생물, 생식 세포 및 배아
- 신생물, 신경 조직
- 신장 신생물
- 기관지 암종
- 기관지 신생물
- 신경내분비종양
- 모반과 흑색종
- 피부 신생물
- 피부 및 결합 조직 질환
- 암종, 신장 세포
- 암종, 비소세포폐
- 흑색종
- 조사 기술
- 치료학
- 임상 실험실 기술
- 진단 기술 및 절차
- 진단
- 수술 절차, 수술
- 화학 기술, 분석
- 스펙트럼 분석
- 방사선 요법
- 전형적인 기술
- 신경 외과 절차
- 시편 처리
- 자기 공명 분광법
- 방사선 수술
기타 연구 ID 번호
기타 연구 ID 번호
- 22350
- P30CA033572 (미국 NIH 보조금/계약)
- 22350 (기타 식별자: City of Hope Medical Center)
- NCI-2023-02155 (레지스트리 식별자: CTRP (Clinical Trial Reporting Program))
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .